Reassessment of Premedication in Surgery (PREMED)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01549691
Recruitment Status : Completed
First Posted : March 9, 2012
Last Update Posted : September 25, 2013
Information provided by (Responsible Party):
University Hospital, Angers

Brief Summary:

The purpose of this study is to test the level of anxiety in patients, the day before surgery (late afternoon) and immediately prior to surgery in 3 parallel groups of patients.

  • one receiving placebo before going to sleep (before sleep), the day prior surgery and placebo when awakening (awakening), the day of surgery
  • one receiving zopiclone (7.5 mg) before sleep and placebo at awakening
  • one receiving placebo before sleep and alprazolam (0.5 mg)at awakening

double blind, randomized controlled study

Condition or disease Intervention/treatment Phase
Anxiety Drug: Zopiclone Drug: Alprazolam Drug: placebo Phase 4

Detailed Description:


  • 18 to 65 years old
  • elective surgery
  • in-hospital preoperative night

Outcome measures:

  • anxiety scales
  • demographic data

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 455 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Assessment of Two Modes of Premedication in Surgery - PREMED Study
Study Start Date : March 2012
Actual Primary Completion Date : April 2013
Actual Study Completion Date : April 2013

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Anxiety
Drug Information available for: Alprazolam

Arm Intervention/treatment
Experimental: zopiclone
zopiclone given before sleep, the day before surgery (placebo given at awakening the day of surgery)
Drug: Zopiclone
7.5 mg before sleep, the evening before surgery
Other Name: Imovane

Experimental: alprazolam
given at awakening, the day of surgery (placebo given before sleep, the day before surgery)
Drug: Alprazolam
0.5 mg at awakening, the day of surgery
Other Name: Xanax

Placebo Comparator: placebo
Placebo given night before operation and the morning of operation
Drug: placebo
given night before surgery and at awakening, the day of surgery

Primary Outcome Measures :
  1. anxiety scales [ Time Frame: duration of the study : 12 hours (one evaluation on late afternoon the day before surgery and the second evaluation on arrival to operating room) ]

    * The day before surgery (late afternoon) : patient's self rating of anxiety and desire of information regarding upcoming surgery (Amsterdam patient anxiety and information scale, APAIS)

    * On arrival to the operating room : Recording of the level of declared anxiety (numeric scale similar to that corresponding of the "anxiety component of the APAIS scale)

Secondary Outcome Measures :
  1. markers of stress [ Time Frame: on arrival to operating room (one single recording) ]

    recording of actual (using the operating room monitor):

    • heart rate (at rest, supine)
    • systolic blood pressure (at rest, supine)

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • age 18-65 years old
  • elective surgery
  • in-hospital night before surgery

Exclusion Criteria:

  • myasthenia gravis
  • chronic intake of psychotropic drugs
  • opiates intake
  • severe obstructive sleep apnea
  • intracranial hypertension
  • morbid obesity
  • myasthenia gravis
  • acute severe medical disorder
  • non health insurance coverage
  • protected patients by law
  • pregnancy
  • non French speaking

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01549691

Clinique Sévigné
Cesson, Bretagne, France, 35576
Dept of Anesthesia, Hôpital Maison Blanche
Reims, Champagne, France, 51092
Dept of Anesthesia, Hôpital Tenon
Paris, Ile de France, France, 75020
Dept of Anesthesia, Hôpital Foch,
Suresnes, Ile de France, France, 92150
Centre Paul Papin
Angers, Maine et Loire, France, 49000
University Hospital
Angers, Maine et Loire, France, 49933
Clinique St Leonard
Trélazé, Maine et Loire, France, 49800
Dept of Anesthesia
Le Mans, Maine, France, 72000
Sponsors and Collaborators
University Hospital, Angers
Study Chair: Laurent Beydon, MD University Hospital Angers (Dept of Anesthesia)

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: University Hospital, Angers Identifier: NCT01549691     History of Changes
Other Study ID Numbers: PHRC 2011-20
2011-002553-65 ( EudraCT Number )
First Posted: March 9, 2012    Key Record Dates
Last Update Posted: September 25, 2013
Last Verified: September 2013

Keywords provided by University Hospital, Angers:
Anti-anxiety agents

Additional relevant MeSH terms:
Hypnotics and Sedatives
Central Nervous System Depressants
Physiological Effects of Drugs
Anti-Anxiety Agents
Tranquilizing Agents
Psychotropic Drugs
GABA Modulators
GABA Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action